NCT00002261已完成1 期
A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers
Bristol-Myers Squibb2 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 试验地点
- 2
研究概览
简要总结
To determine the physiological and immunological responses in healthy HIV seronegative adult volunteers vaccinated with a) the HIVAC-1e (vaccinia-HIV) vaccine expressing the envelope glycoproteins of HIV and b) the Wyeth smallpox vaccine. The parameters to be studied will include:
- The course of physiological responses to vaccination, including (a) lesion development, progression, and resolution; (b) physiological changes such as temperature, malaise, itching at the site, etc. and (c) any observable AE.
- The appearance, identity, quantity, and duration of humoral antibodies against HIV and vaccinia virus.
- The appearance, identity, quantity, and duration of cell-mediated immunity against HIV and vaccinia virus.
- The adequacy of a procedure using a special dressing to contain viral shedding from the vaccination site.
- The safety, humoral and cellular immune responses of a booster injection of the recombinant subunit gp160 vaccine (MicroGeneSys) in HIVAC-1e recipients.
研究设计
- 研究类型
- Interventional
- 主要目的
- Prevention
入排标准
- 年龄范围
- 18 Years 至 60 Years(Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Monotherapy Versus Placebo Over 10 Days in Integrase Naive HIV-1 Infected AdultsInfection, Human Immunodeficiency VirusHIV-1 InfectionNCT00398125GlaxoSmithKline30
已完成
3 期
Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)HIV InfectionsNCT03446573ViiV Healthcare743
已完成
2 期
H1N1 Vaccine at Two Dose Levels in HIV Positive AdultsInfluenzaNCT00992433National Institute of Allergy and Infectious Diseases (NIAID)192
已完成
3 期
Can Valacyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2?Human Immunodeficiency VirusHerpes SimplexNCT01176409University Health Network, Toronto60
已完成
1 期
A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency VirusHIV InfectionsNCT00000683National Institute of Allergy and Infectious Diseases (NIAID)54
